ArticleInternal medicine (Tokyo, Japan)2018
Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma.
Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Immune checkpoint inhibitor-associated hepatotoxicity and ileitis: a diagnostic challenge in a patient on long-term nivolumab therapy.Oxford medical case reports · 2026Article
- Article
- Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review.Molecular biology reports · 2024Review
- Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review.Cancer pathogenesis and therapy · 2023Review
- A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.Diagnostics (Basel, Switzerland) · 2022Article
- Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives.Frontiers in pharmacology · 2022Review
- Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.Frontiers in immunology · 2022Review
- Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Checkpoint Inhibitors and Hepatotoxicity.Biomedicines · 2021Review
- Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma.Case reports in oncological medicine · 2021Article
- Hepatobiliary and Pancreatic Adverse Events.Advances in experimental medicine and biology · 2021Article
- When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report.Journal for immunotherapy of cancer · 2020Review
- Review
- Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.Hepatology communications · 2020Review
- Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings.World journal of gastrointestinal pathophysiology · 2019Review
- Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.Journal of clinical medicine research · 2019Review
- Drug-Induced Liver Injury: Highlights of the Recent Literature.Drug safety · 2019Review
- 5-Aminosalicylic Acid-Induced Liver Injury in a Patient with Ulcerative Colitis: A Case Report.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 42-year-old man was diagnosed with cStage IIIb malignant melanoma and underwent resection. After interferon-beta therapy, 18-fluorodeoxyglucose-positron emission tomography/computed tomography (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.